Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.

@article{Walker2006IntraperitonealCO,
  title={Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.},
  author={Joan L. Walker and Deborah K. Armstrong and Helen Q Huang and Jeffrey Fowler and Kenneth Webster and Robert A. Burger and Daniel L. Clarke-Pearson},
  journal={Gynecologic oncology},
  year={2006},
  volume={100 1},
  pages={27-32}
}
OBJECTIVES To evaluate reasons for discontinuing intraperitoneal (IP) chemotherapy, and to compare characteristics of patients who did versus did not successfully complete six cycles of IP chemotherapy. METHODS In a phase III trial, women with optimal stage III ovarian or peritoneal carcinoma were randomly allocated to receive IP therapy (paclitaxel 135 mg/m(2) intravenously (IV) over 24 h, cisplatin 100 mg/m(2) IP day 2, paclitaxel 60 mg/m(2) IP day 8) every 21 days for six cycles. Patients… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 97 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Intraperitoneal catheter outcomes on GOG 172: randomized trial of IV vs. IP chemotherapy in optimal ovarian cancer

  • JL Walker, DK Armstrong, BN Bundy
  • Gynecol Oncol
  • 2004

Similar Papers

Loading similar papers…